Forte Biosciences, Inc. (FBRX)
NASDAQ: FBRX · Real-Time Price · USD
10.98
+0.28 (2.62%)
Feb 21, 2025, 4:00 PM EST - Market closed
Company Description
Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States.
The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata.
Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Forte Biosciences, Inc.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 9 |
| CEO | Paul A. Wagner |
Contact Details
Address: 3060 Pegasus Park Drive, Building 6 Dallas, Texas 75247 United States | |
| Phone | 310 618 6994 |
| Website | fortebiorx.com |
Stock Details
| Ticker Symbol | FBRX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001419041 |
| CUSIP Number | 34962G109 |
| ISIN Number | US34962G1094 |
| Employer ID | 26-1243872 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Paul A. Wagner Ph.D. | Chief Executive Officer, President and Chairman |
| Antony A. Riley CPA | Chief Financial Officer |
| Dr. Barbara K. Finck M.D. | Chief Medical Clinician and Director |
| Christopher Roenfeldt | Chief Operating Officer |
| Steven Ruhl | Chief Technical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 13, 2025 | SCHEDULE 13G | Filing |
| Feb 10, 2025 | SCHEDULE 13G/A | Filing |
| Feb 7, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |